Therapeutic antibodies for infectious diseases

Affiliations

¹ School of Public Health and Community Medicine, University of New South Wales, Samuels Avenue, Kensington, Sydney, NSW 2033, Australia .
² Initiative for Vaccine Research, World Health Organization, Geneva, Switzerland .
³ Sydney Medical School Northern, University of Sydney, Sydney, Australia .

Erin Sparrow et al. Bull World Health Organ. 2017.

. 2017 Mar 1;95(3):235-237.

doi: 10.2471/BLT.16.178061. Epub 2017 Feb 2.

¹ School of Public Health and Community Medicine, University of New South Wales, Samuels Avenue, Kensington, Sydney, NSW 2033, Australia .
² Initiative for Vaccine Research, World Health Organization, Geneva, Switzerland .
³ Sydney Medical School Northern, University of Sydney, Sydney, Australia .

No abstract available

References

1. Blencowe H, Lawn J, Vandelaer J, Roper M, Cousens S. Tetanus toxoid immunization to reduce mortality from neonatal tetanus. Int J Epidemiol. 2010. April;39 Suppl 1:i102–9. 10.1093/ije/dyq027 - DOI - PMC - PubMed
1. Keller MA, Stiehm ER. Passive immunity in prevention and treatment of infectious diseases. Clin Microbiol Rev. 2000. October;13(4):602–14. 10.1128/CMR.13.4.602-614.2000 - DOI - PMC - PubMed
1. Ian Gust AO. Role of passive immunotherapies in managing infectious outbreaks. Biologicals. 2012. May;40(3):196–9. 10.1016/j.biologicals.2012.01.001 - DOI - PubMed
1. Graham BS, Ambrosino DM. History of passive antibody administration for prevention and treatment of infectious diseases. Curr Opin HIV AIDS. 2015. May;10(3):129–34. 10.1097/COH.0000000000000154 - DOI - PMC - PubMed
1. Immune globulins [Internet]. Silver Spring: US Food and Drug Administration; 2016. Available from: http://www.fda.gov/BiologicsBloodVaccines/BloodBloodProducts/ApprovedPro...http://[cited 2016 Oct 8].